{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Prostate+Cancer+AJCC+v7&page=5", "query": { "condition": "Stage IV Prostate Cancer AJCC v7", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 395, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Prostate+Cancer+AJCC+v7&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Prostate+Cancer+AJCC+v7&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T14:21:33.784Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01026623", "title": "Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2009-10", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2019-06-17", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 4, "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • New York, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026623" }, { "nct_id": "NCT03406858", "title": "Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "PSA Progression", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "HER2Bi-Armed Activated T Cells", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2018-06-07", "completion_date": "2022-11-07", "has_results": true, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03406858" }, { "nct_id": "NCT03419234", "title": "Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma in the Soft Tissue", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Androgen deprivation therapy", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 223, "start_date": "2018-04-26", "completion_date": "2028-04-01", "has_results": true, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 665, "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03419234" }, { "nct_id": "NCT00080678", "title": "Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 116, "start_date": "2003-05", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-10-12", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080678" }, { "nct_id": "NCT00026377", "title": "SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "bicalutamide", "type": "DRUG" }, { "name": "flutamide", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "SU5416", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 3, "start_date": "2001-11", "completion_date": "2003-04", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 3, "location_summary": "Chicago, Illinois • LaGrange, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "LaGrange", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026377" }, { "nct_id": "NCT02023463", "title": "Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Goserelin acetate", "type": "DRUG" }, { "name": "Leuprolide acetate", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 25, "start_date": "2014-04-02", "completion_date": "2040-01-01", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02023463" }, { "nct_id": "NCT00956163", "title": "Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Bone Metastases", "Recurrent Prostate Cancer", "Stage I Prostate Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "fluorine F 18 sodium fluoride", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "technetium Tc 99m methylene diphosphonate", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2010-03", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-07-02", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00956163" }, { "nct_id": "NCT00003517", "title": "Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Stage III Prostate Cancer", "Stage IV Prostate Cancer", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "antineoplaston A10", "type": "DRUG" }, { "name": "antineoplaston AS2-1", "type": "DRUG" }, { "name": "bicalutamide", "type": "DRUG" }, { "name": "flutamide", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "alternative product therapy", "type": "PROCEDURE" }, { "name": "antiandrogen therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "biologically based therapies", "type": "PROCEDURE" }, { "name": "cancer prevention intervention", "type": "PROCEDURE" }, { "name": "complementary and alternative therapy", "type": "PROCEDURE" }, { "name": "differentiation therapy", "type": "PROCEDURE" }, { "name": "endocrine therapy", "type": "PROCEDURE" }, { "name": "hormone therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003517" }, { "nct_id": "NCT03217747", "title": "Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Castration-Resistant Prostate Carcinoma", "Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Metastatic Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Refractory Malignant Solid Neoplasm", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Ivuxolimab", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Utomilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2017-08-02", "completion_date": "2026-04-30", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03217747" }, { "nct_id": "NCT00003183", "title": "Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hope Cancer Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 64, "start_date": "1997-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-03T14:21:33.784Z", "location_count": 2, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003183" } ] }